Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

Caroline Bodet-Milin; Alain Faivre-Chauvet; Thomas Carlier; Catherine Ansquer; Aurore Rauscher; Eric Frampas; Frederique Toulgoat; Damien Masson; Mickael Bourgeois; Evelyne Cerato; Vincent Rohmer; Olivier Couturier; Delphine Drui; David M. Goldenberg; Robert M. Sharkey; Jacques Barbet; Francoise Kraeber-Bodere

doi:10.2967/jnumed.120.252791

Research ArticleOncology

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, Frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, Delphine Drui, David M. Goldenberg, Robert M. Sharkey, Jacques Barbet and Francoise Kraeber-Bodere

Journal of Nuclear Medicine September 2021, 62 (9) 1221-1227; DOI: https://doi.org/10.2967/jnumed.120.252791

Caroline Bodet-Milin

1Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alain Faivre-Chauvet

1Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas Carlier

1Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Catherine Ansquer

1Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Aurore Rauscher

2Pharmacy Unit, ICO Cancer Center, Saint-Herblain, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Eric Frampas

1Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France;

2Pharmacy Unit, ICO Cancer Center, Saint-Herblain, France;

3Radiology Department, University Hospital, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frederique Toulgoat

3Radiology Department, University Hospital, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Damien Masson

4Biology Department, University Hospital, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mickael Bourgeois

1Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Evelyne Cerato

5Délégation à la Recherche Clinique et à l’Innovation, University Hospital, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vincent Rohmer

6Endocrinology Department, University Hospital, Angers, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Olivier Couturier

7Nuclear Medicine Department, University Hospital, Angers, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Delphine Drui

8Endocrinology Department, University Hospital, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David M. Goldenberg

9IBC Pharmaceuticals, Inc., Morris Plains, New Jersey;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Robert M. Sharkey

10Immunomedics, Inc., Morris Plains, New Jersey; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jacques Barbet

11GIP Arronax, Saint-Herblain, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Francoise Kraeber-Bodere

1Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue 9

September 1, 2021

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

Journal of Nuclear Medicine Sep 2021, 62 (9) 1221-1227; DOI: 10.2967/jnumed.120.252791

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

Journal of Nuclear Medicine Sep 2021, 62 (9) 1221-1227; DOI: 10.2967/jnumed.120.252791

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Oncology

Radioimmunotherapy in Oncology
The Role of NAC FDG-PET/CT in Detecting Cutaneous Lesions
Quantitative assessment of radiation therapy-induced cardiovascular complications with FDG-PET and NaF-PET imaging in lung cancer and other thoracic malignancies

Show more Oncology

Clinical

Addition of ¹³¹I-MIBG to PRRT (⁹⁰Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
SUVs Are Adequate Measures of Lesional ¹⁸F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?

Show more Clinical

Keywords

immuno-PET
MTC
carcinoembryonic antigen
bispecific antibody
pretargeted radioimmunoimaging

Main menu

User menu

Search

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Oncology

Clinical

Similar Articles

Keywords